Camrelizumab Carboplatin Nab-Paclitaxel ES-SCLC Efficacy
Here’s a breakdown of the key details from the provided text, focusing on a new study regarding treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC):
Key Findings & study Details:
Treatment Combination: The study investigated the combination of camrelizumab (a PD-1 inhibitor) with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for ES-SCLC.
Positive Outcomes: The combination showed promise, and the study identified biomarkers associated with patient outcomes.
Patient Population: 60 patients with ES-SCLC were enrolled (March 2021 – December 2022).
Median age: 65 years (range 38-74)
Mostly male (50 out of 60)
majority were former smokers (40/60)
Good performance status (all had an ECOG of 1)
Most had Stage IV disease at diagnosis (52/60)
Treatment Schedule:
Camrelizumab + Carboplatin + Nab-paclitaxel every 3 weeks for 4-6 cycles.
Maintenance camrelizumab until disease progression or unacceptable toxicity.
Follow-up: Median follow-up was 19.3 months.
Ongoing Treatment: 10 patients (16.7%) were still receiving treatment at the time of analysis.
Reasons for Discontinuation:
Disease progression (60%)
Patient decision (11.7%)
Adverse events (10%)
Context & Importance:
Limited First-Line Options: Current first-line chemotherapy options for ES-SCLC are limited.
Irinotecan Issues: Irinotecan is underutilized due to toxicity and limited survival benefit.
PD-1 Blockade Success: PD-1 blockade has shown effectiveness in ES-SCLC.
nab-Paclitaxel Benefits: Nab-paclitaxel (albumin-bound and solvent-free) may reduce the toxicity typically associated with paclitaxel.
High Percentage of Late Diagnosis: Approximately 75% of SCLC patients are diagnosed at the extensive stage.
Where the study was published: Medcomm journal.